{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/osteoporosis-prevention-of-fragility-fractures/management/management/","result":{"pageContext":{"chapter":{"id":"85598d9c-79e5-5925-8dee-46b4cd8f2170","slug":"management","fullItemName":"Scenario: Management","depth":2,"htmlHeader":"<!-- begin field 552919bc-3d31-4e50-a951-8e0cd2e4e0fd --><h2>Scenario: Management</h2><!-- end field 552919bc-3d31-4e50-a951-8e0cd2e4e0fd -->","summary":"Covers the management of a person at risk of fragility fracture in primary care.","htmlStringContent":"<!-- begin item 7f3bca00-bf31-4d99-99c5-1b73d8a9d617 --><!-- begin field 90efb6ac-a12f-4593-8779-acbd0087f6dc --><p>From age 18 years onwards.</p><!-- end field 90efb6ac-a12f-4593-8779-acbd0087f6dc --><!-- end item 7f3bca00-bf31-4d99-99c5-1b73d8a9d617 -->","topic":{"id":"9f86812a-068c-512b-a1a4-07fda4301d21","topicId":"a4e2c95c-bf7f-4277-b693-c3b2761380ed","topicName":"Osteoporosis - prevention of fragility fractures","slug":"osteoporosis-prevention-of-fragility-fractures","lastRevised":"Last revised in May 2020","chapters":[{"id":"f651cf3f-ec13-5c52-9121-2dd61c54dc3c","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"55fa9b49-e88f-5e9b-8156-01352a4c94b5","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"a36d9df6-8dba-581c-9361-7b771a120859","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"0562cda5-80f8-5d79-83f3-f1233a8060e3","slug":"changes","fullItemName":"Changes"},{"id":"8adeb7b7-191a-5ba3-96f4-d25461c0b901","slug":"update","fullItemName":"Update"}]},{"id":"753ec6fc-9992-587b-870c-2a54cddd30c8","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"62fbf7e5-b097-5a47-af2f-56553c8b16fb","slug":"goals","fullItemName":"Goals"},{"id":"e2d42919-7f54-594f-bcb8-06f2625a550f","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"eca5799e-0969-539e-b27e-e8ed22c5cc54","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"355020b6-9455-5e78-8a1a-172fc947a117","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"3c308a4e-8074-5dca-a9bd-a56405a0595f","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"745ec600-96ff-5056-8ab4-7ebb02e5286d","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"4541ac61-d9f8-5c7e-a415-a2f3b57c3f45","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"36908082-d612-5f9e-8dd3-09d9bc87bf79","slug":"definition","fullItemName":"Definition"},{"id":"127d59dc-ce73-51b5-80c0-d57209058280","slug":"causes","fullItemName":"Causes"},{"id":"4349db35-6c86-5ebc-a13f-6a1dce22e466","slug":"complications","fullItemName":"Complications"},{"id":"710ee28b-5971-5b43-ac4e-22ac6fba154d","slug":"prevalence","fullItemName":"Prevalence"},{"id":"c62b535b-c8d0-5ce1-93bb-867c8644eb2f","slug":"risk-factors","fullItemName":"Risk factors"}]},{"id":"35af4f9e-0536-527c-8b94-94cd5f1fa796","fullItemName":"Management","slug":"management","subChapters":[{"id":"bf661812-0f6f-57a2-b0ab-530b799fc4c4","slug":"assessment","fullItemName":"Scenario: Assessment"},{"id":"85598d9c-79e5-5925-8dee-46b4cd8f2170","slug":"management","fullItemName":"Scenario: Management"}]},{"id":"f0656a98-39c4-59de-aebb-3eebb0d8dc40","fullItemName":"Prescribing information","slug":"prescribing-information","subChapters":[{"id":"38706564-322f-50d2-a7e2-7fe637b76407","slug":"calcium-colecalciferol-vitamin-d3-preparations","fullItemName":"Calcium and colecalciferol (vitamin D3) preparations"},{"id":"0d9951b1-3165-5af5-9601-e12d45a17a6c","slug":"bisphosphonates","fullItemName":"Bisphosphonates"}]},{"id":"c086cbd6-b967-579e-9768-901abfa8d3ca","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"726389ef-f472-5512-a1bf-bf15159602fd","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"f476f450-a081-5a31-a23e-7b837233a18e","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"393e0faf-da4e-5bd5-b705-179c32a6c50b","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"b11023db-83b9-5207-b99c-7917bef26190","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"0b683807-10ff-54fc-936a-06d71aa6f8d4","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"fb240203-2f82-5b14-85ec-55933467aceb","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"782a2ad0-e9ec-5fc2-b2e1-95ec79f6a2f8","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"35af4f9e-0536-527c-8b94-94cd5f1fa796","slug":"management","fullItemName":"Management"},"subChapters":[{"id":"aa40d4a1-51e5-5400-83f1-eec4f723b5e1","slug":"interpretation-of-results","fullItemName":"Interpretation of results","depth":3,"htmlHeader":"<!-- begin field ede207c4-12aa-43dd-8757-0f4f1853f631 --><h3>How should I manage fragility fracture risk scores?</h3><!-- end field ede207c4-12aa-43dd-8757-0f4f1853f631 -->","summary":null,"htmlStringContent":"<!-- begin item 0cb83915-021d-4e96-af0a-daf79db8bb6c --><!-- begin field c8d759e4-64f2-4def-94ea-c0d9d3f03ca4 --><ul><li><strong>For people at high risk of fragility fracture</strong><ul><li>For people<strong> </strong>whose fracture risk is above the recommended threshold, offer a dual-energy x-ray absorptiometry (DXA) scan, then bone-sparing drug treatment if the T-score is -2.5 or less. </li><li>If the T-score is greater than -2.5, modify risk factors  where possible (see the section on <a class=\"topic-reference internal-reference\" href=\"/topics/osteoporosis-prevention-of-fragility-fractures/background-information/risk-factors/\">Risk factors</a>), treat any underlying conditions (see the section on <a class=\"topic-reference internal-reference\" href=\"/topics/osteoporosis-prevention-of-fragility-fractures/background-information/causes/\">What causes osteoporosis and osteoporotic fractures?</a>), and repeat the DXA at an interval appropriate for the person based on their risk profile, using clinical judgement (but usually within 2 years). For more information, see the section on <a class=\"topic-reference internal-reference\" href=\"/topics/osteoporosis-prevention-of-fragility-fractures/management/management/#follow-up\">How should I follow up a person at risk of fragility fracture?</a>.</li></ul></li><li><strong>For people at intermediate risk</strong><strong> of fragility fracture</strong><ul><li>For people whose fracture risk is close to the recommended threshold and who have risk factors that may be underestimated by <a href=\"http://www.shef.ac.uk/FRAX/tool.jsp\" data-hyperlink-id=\"513b7488-0cf9-45c8-be85-a992016ca873\">FRAX®</a> (see the section <a class=\"topic-reference internal-reference\" href=\"/topics/osteoporosis-prevention-of-fragility-fractures/management/assessment/#interpretation-of-fracture-risk-scores\">How should I interpret a fragility fracture risk score?</a>), arrange a DXA scan to measure their bone mineral density (BMD) and offer drug treatment if the T-score is -2.5 or less.</li></ul></li><li><strong>For people at low risk of fragility fracture</strong><ul><li>For people whose fracture risk is below the recommended threshold, do not offer drug treatment, offer lifestyle advice and follow up within 5 years. See the section on <a class=\"topic-reference internal-reference\" href=\"/topics/osteoporosis-prevention-of-fragility-fractures/management/management/#lifestyle-information-advice\">What lifestyle information and advice should I give?</a>.</li></ul></li></ul><!-- end field c8d759e4-64f2-4def-94ea-c0d9d3f03ca4 --><!-- end item 0cb83915-021d-4e96-af0a-daf79db8bb6c -->","subChapters":[{"id":"d1191b24-80c7-5860-adc7-db6e6bd9c8aa","slug":"basis-for-recommendation-c24","fullItemName":"Basis for recommendation","depth":4,"htmlHeader":"<!-- begin field b5e11930-fa73-4889-9b73-454cfe455d17 --><h4>Basis for recommendation</h4><!-- end field b5e11930-fa73-4889-9b73-454cfe455d17 -->","summary":null,"htmlStringContent":"<!-- begin item c24dc558-cc28-4cc3-bed6-43bf6c13ca73 --><!-- begin field 299714a4-203c-48a1-adab-120284b8def7 --><p>These recommendations are based on the National Institute for Health and Care Excellence (NICE) guideline <em>Osteoporosis: assessing the risk of fragility fracture </em>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/osteoporosis-prevention-of-fragility-fractures/references/\">NICE, 2012b</a>] and the Scottish Intercollegiate Guidelines Network (SIGN) guideline <em>Management of osteoporosis and the prevention of fragility fractures</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/osteoporosis-prevention-of-fragility-fractures/references/\">SIGN, 2015</a>].</p><!-- end field 299714a4-203c-48a1-adab-120284b8def7 --><!-- end item c24dc558-cc28-4cc3-bed6-43bf6c13ca73 -->","subChapters":[]}]},{"id":"d8be0cf3-1b3c-5c6c-9f49-a7293323f6bd","slug":"drug-treatment","fullItemName":"Drug treatment","depth":3,"htmlHeader":"<!-- begin field 5015a4fe-f800-4b1f-bf8b-85a5c26c9cd9 --><h3>What drug treatments are recommended for people at high risk of osteoporotic fracture?</h3><!-- end field 5015a4fe-f800-4b1f-bf8b-85a5c26c9cd9 -->","summary":null,"htmlStringContent":"<!-- begin item 9ce0751f-3c6f-4f22-8f19-43a746a6c77f --><!-- begin field daf9b255-30ae-44fa-af68-8393ab0f0e3d --><ul><li><strong>If bone-sparing treatment is recommended, prescribe a bisphosphonate</strong> (alendronate 10 mg once daily or 70 mg once weekly, or risedronate<strong> </strong>5 mg once daily or 35 mg once weekly),<strong> </strong>if there are no contraindications and after appropriate counselling to:<ul><li>Postmenopausal women and men over 50 years of age who have been confirmed by dual-energy X-ray absorptiometry (DXA) scan to have osteoporosis (bone mineral density [BMD] T-score of -2.5 or less).</li><li>Consider prescribing to:<ul><li>People who are taking high doses of oral corticosteroids (more than or equivalent to prednisolone 7.5 mg daily for 3 months or longer).</li></ul></li><li>All the bisphosphonates are licensed for use in postmenopausal women. However, only alendronate (once-daily tablets) and risedronate (once-weekly tablets) are licensed for use in men.</li><li>Counsel people on the use of bisphosphonates (for more information, see the section on <a class=\"topic-reference internal-reference\" href=\"/topics/osteoporosis-prevention-of-fragility-fractures/prescribing-information/bisphosphonates/#advice\">What advice should I give a person taking a bisphosphonate?</a>) and explain about possible adverse effects (for more information, see the section on <a class=\"topic-reference internal-reference\" href=\"/topics/osteoporosis-prevention-of-fragility-fractures/prescribing-information/bisphosphonates/#adverse-effects\">What are the adverse effects of bisphosphonates?</a>).</li><li>If an oral bisphosphonate is not tolerated or is contraindicated, consider specialist referral. Specialist treatment options include zoledronic acid, strontium ranelate, raloxifene, denosumab, and teriparatide. </li></ul></li><li><strong>If the person's calcium intake is adequate</strong> (700 mg/day), prescribe 10 micrograms (400 international units) of vitamin D (without calcium) for people not exposed to much sunlight. See the section on <a class=\"topic-reference internal-reference\" href=\"/topics/osteoporosis-prevention-of-fragility-fractures/management/assessment/#how-to-assess\">How should I assess a person for fragility fracture risk?</a>).</li><li><strong>If calcium intake is inadequate:</strong><ul><li>Prescribe 10 micrograms (400 international units) of vitamin D with at least 1000 mg of calcium daily. </li><li>Prescribe 20 micrograms (800 international units) of vitamin D with at least 1000 mg of calcium daily for elderly people who are housebound or living in a nursing home.  </li></ul></li><li><strong>Consider prescribing hormone replacement therapy (HRT) </strong><strong>to women who have a premature menopause</strong> (menopause before 40 years of age) to reduce the risk of fragility fractures and for the relief of menopausal symptoms. For further information on prescribing HRT, see the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/menopause/\">Menopause</a>.</li></ul><!-- end field daf9b255-30ae-44fa-af68-8393ab0f0e3d --><!-- end item 9ce0751f-3c6f-4f22-8f19-43a746a6c77f -->","subChapters":[{"id":"cf3e3d82-4c4b-5de2-9ca8-0e7ab4a5952e","slug":"basis-for-recommendation-4e9","fullItemName":"Basis for recommendation","depth":4,"htmlHeader":"<!-- begin field 6972c2c6-a2b6-4107-a3b0-2c590ccb4dbd --><h4>Basis for recommendation</h4><!-- end field 6972c2c6-a2b6-4107-a3b0-2c590ccb4dbd -->","summary":null,"htmlStringContent":"<!-- begin item 4e97638c-8b3c-41dd-9d1f-347f0d0d8a93 --><!-- begin field 999c61cd-bd15-4932-b9de-fbe3bceeeaf8 --><p>These recommendations are based on the National Institute for Health and Care Excellence (NICE) guideline <em>Osteoporosis: assessing the risk of fragility fracture</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/osteoporosis-prevention-of-fragility-fractures/references/\">NICE, 2012b</a>], the Scottish Intercollegiate Guidelines Network (SIGN) guideline <em>Management of osteoporosis and the prevention of fragility fractures </em>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/osteoporosis-prevention-of-fragility-fractures/references/\">SIGN, 2015</a>], the National Osteoporosis Guideline Group (NOGG) guideline <em>Osteoporosis: clinical guideline for prevention and treatment</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/osteoporosis-prevention-of-fragility-fractures/references/\">NOGG, 2016</a>], and a Cochrane systematic review [<a class=\"bibliography-reference internal-reference\" href=\"/topics/osteoporosis-prevention-of-fragility-fractures/references/\">Marjoribanks, 2012</a>].<br><strong>Bisphosphonates</strong></p><ul><li>The recommendation to consider prescribing bisphosphonates to prevent fragility fracture is based on evidence that they reduce the risk of vertebral fracture, non-vertebral fracture, and hip fracture [<a class=\"bibliography-reference internal-reference\" href=\"/topics/osteoporosis-prevention-of-fragility-fractures/references/\">SIGN, 2015</a>]. </li></ul><p><strong>People using oral corticosteroids </strong>The recommendation to consider prescribing bone-sparing treatment to people who are taking high doses of corticosteroids is based on evidence that:</p><ul><li>The corticosteroid dose and the duration of therapy is directly associated with the risk of fracture [<a class=\"bibliography-reference internal-reference\" href=\"/topics/osteoporosis-prevention-of-fragility-fractures/references/\">SIGN, 2015</a>].</li><li>Corticosteroids may affect bone quality, bone density as well as other risk factors for fragility fracture [<a class=\"bibliography-reference internal-reference\" href=\"/topics/osteoporosis-prevention-of-fragility-fractures/references/\">SIGN, 2015</a>].</li></ul><p><strong>Specialist</strong><strong> referral if oral bisphosphonate not tolerated or are contraindicated</strong></p><ul><li>CKS recommends referring people for specialist management if oral bisphosphonates are not tolerated or are contraindicated. This recommendation is based on the availability, cost, and risks of adverse effects of alternatives (for example zoledronic acid, raloxifene, denosumab, and teriparatide) compared with oral bisphosphonates. </li></ul><p><strong>Calcium and vitamin D supplementation</strong><br>The recommendation to consider prescribing calcium and vitamin D instead of advising people to increase their dietary intake is based on: </p><ul><li>High-quality trials which indicate that calcium is required in addition to vitamin D to reduce fracture risk if intake of dietary calcium is inadequate [<a class=\"bibliography-reference internal-reference\" href=\"/topics/osteoporosis-prevention-of-fragility-fractures/references/\">SIGN, 2015</a>]. </li><li>A lack of evidence to support increasing dietary calcium intake to reduce fracture risk [<a class=\"bibliography-reference internal-reference\" href=\"/topics/osteoporosis-prevention-of-fragility-fractures/references/\">SIGN, 2015</a>].<ul><li>Studies assessing the effects of calcium on fracture risk are of low quality and meta-analyses have reported considerable heterogeneity [<a class=\"bibliography-reference internal-reference\" href=\"/topics/osteoporosis-prevention-of-fragility-fractures/references/\">SIGN, 2015</a>].</li></ul></li></ul><p><strong>Prescribing hormone replacement therapy (HRT)</strong></p><ul><li>The recommendation to consider prescribing HRT to younger postmenopausal women is based on evidence from a Cochrane systematic review of 19 trials (n = 42,830) which investigated the long-term effect of HRT and found that there were significant reductions in the risk of fracture and menopausal symptoms [<a class=\"bibliography-reference internal-reference\" href=\"/topics/osteoporosis-prevention-of-fragility-fractures/references/\">Marjoribanks, 2012</a>].</li></ul><!-- end field 999c61cd-bd15-4932-b9de-fbe3bceeeaf8 --><!-- end item 4e97638c-8b3c-41dd-9d1f-347f0d0d8a93 -->","subChapters":[]}]},{"id":"371826f5-dc62-569c-aabe-a61d6a6cef22","slug":"lifestyle-information-advice","fullItemName":"Lifestyle information and advice","depth":3,"htmlHeader":"<!-- begin field 2cf13a15-4ca1-43cf-bf1a-64a6f232d504 --><h3>What lifestyle information and advice should I give?</h3><!-- end field 2cf13a15-4ca1-43cf-bf1a-64a6f232d504 -->","summary":null,"htmlStringContent":"<!-- begin item c50e9740-06ab-4980-8de3-7088629d6233 --><!-- begin field e476dfe5-c6f8-4d60-882d-2fb0b9bcaceb --><ul><li><strong>Advise the person to:</strong><ul><li><strong>Take regular exercise </strong>(tailored to the person) to improve muscle strength. Encourage:<ul><li>Walking, especially outdoors, as this will increase exposure to sunlight, increasing vitamin D production.</li><li>Strength training (such as weight training) of different muscle groups (for example hip, wrist, and spine).</li><li>A combination of exercise types, for example balance, flexibility, stretching, endurance, and progressive strengthening exercises. </li></ul></li></ul><ul><li><strong>Eat a balanced diet </strong>as this may improve bone health.</li><li><strong>Stop smoking if needed, </strong>as it is a risk factor for fragility fracture.<strong> </strong>For more information, see the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/smoking-cessation/\">Smoking cessation</a>.</li><li><strong>Drink alcohol within recommended limits, </strong>as alcohol is a dose-dependent risk factor for fragility fracture. See the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/alcohol-problem-drinking/\">Alcohol - problem drinking</a>.</li></ul></li><li><strong>Provide the person with sources of information and support</strong>:<ul><li><strong><a data-hyperlink-id=\"a8a9996b-1e26-47b3-b373-a98d00039710\" href=\"http://www.nos.org.uk/\">The National Osteoporosis Society</a></strong> provides support and information to people affected by osteoporosis, and works to improve public understanding of osteoporosis.</li><li><strong><a data-hyperlink-id=\"c25ef1ab-fdb6-4e21-b6d7-a98d000397f3\" href=\"https://healthtalk.org/\">Healthtalkonline</a></strong> has a large collection of videos and transcripts of people's experiences of health and illness, including osteoporosis. There are also short articles for people with osteoporosis and the general public.</li><li><strong><a data-hyperlink-id=\"219947c2-43b2-4b55-bbd1-a98d00039862\" href=\"https://www.nhs.uk/conditions/\">NHS</a></strong> has a health encyclopaedia which has a printable article on <a data-hyperlink-id=\"6084f10b-bc5a-4d21-a801-a98d000398e6\" href=\"https://www.nhs.uk/conditions/osteoporosis/\">Osteoporosis</a>. </li></ul></li></ul><!-- end field e476dfe5-c6f8-4d60-882d-2fb0b9bcaceb --><!-- end item c50e9740-06ab-4980-8de3-7088629d6233 -->","subChapters":[{"id":"0c5fcd16-dca2-529c-bada-cd7d84c649ce","slug":"basis-for-recommendation-bf5","fullItemName":"Basis for recommendation","depth":4,"htmlHeader":"<!-- begin field ffaea1e4-382f-4aaa-9b0c-7be84674dc0f --><h4>Basis for recommendation</h4><!-- end field ffaea1e4-382f-4aaa-9b0c-7be84674dc0f -->","summary":null,"htmlStringContent":"<!-- begin item bf5d71f7-4832-40d7-b021-79086ca58f19 --><!-- begin field f7537ccb-acf4-4bab-9c57-c67ca59793b4 --><p>These recommendations are based on the National Institute for Health and Care Excellence (NICE) guideline <em>Osteoporosis: assessing the risk of fragility fracture</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/osteoporosis-prevention-of-fragility-fractures/references/\">NICE, 2012b</a>], the Scottish Intercollegiate Guidelines Network (SIGN) guideline <em>Management of osteoporosis and the prevention of fragility fractures</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/osteoporosis-prevention-of-fragility-fractures/references/\">SIGN, 2015</a>], a Cochrane systematic review of 159 randomized controlled trials (RCTs, n = 79,193) which assessed the effect of interventions designed to prevent falls in older people living in the community [<a class=\"bibliography-reference internal-reference\" href=\"/topics/osteoporosis-prevention-of-fragility-fractures/references/\">Gillespie et al, 2012</a>], a meta-analysis of 10 prospective cohort studies which assessed the effect of smoking on fracture risk [<a class=\"bibliography-reference internal-reference\" href=\"/topics/osteoporosis-prevention-of-fragility-fractures/references/\">Kanis, 2005</a>], and the World Health Organization (WHO) report <em>Assessment of osteoporosis at the primary health care level </em>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/osteoporosis-prevention-of-fragility-fractures/references/\">Kanis, 2008</a>].</p><h5>Taking regular exercise</h5><ul><li>The recommendation to take regular exercise is based on: <ul><li>A Cochrane systematic review that assessed the evidence from 159 RCTs  (n = 79,193) on interventions for preventing falls in older people living in the community and found that exercise reduces the rate of falls and the risk of fracture [<a class=\"bibliography-reference internal-reference\" href=\"/topics/osteoporosis-prevention-of-fragility-fractures/references/\">Gillespie et al, 2012</a>].</li><li>The SIGN guideline, which states that some forms of exercise (such as single leg standing) slow the decline of hip bone mineral density (BMD), while others (weight training) slow the decline of femoral neck BMD [<a class=\"bibliography-reference internal-reference\" href=\"/topics/osteoporosis-prevention-of-fragility-fractures/references/\">SIGN, 2015</a>].</li></ul></li></ul><h5>Eating a balanced diet</h5><ul><li>The recommendation to eat a balanced diet is based on the expert opinion of the NICE guideline development group; however, there is no evidence that specific diets reduce fracture risk [<a class=\"bibliography-reference internal-reference\" href=\"/topics/osteoporosis-prevention-of-fragility-fractures/references/\">NICE, 2012b</a>].</li></ul><h5>Stopping smoking</h5><ul><li>The recommendation to stop smoking is based on indirect evidence from 10 cohort studies (n = 59,232), which suggests that stopping smoking may reduce the risk of osteoporotic fragility fracture in women [<a class=\"bibliography-reference internal-reference\" href=\"/topics/osteoporosis-prevention-of-fragility-fractures/references/\">Kanis, 2005</a>]. </li><li>CKS has extrapolated this recommendation to cover men at risk of osteoporotic fragility fracture.</li></ul><h5>Recommended alcohol consumption</h5><ul><li>The recommendation to consume alcohol within recommended limits is based on evidence of an association between alcohol consumption and osteoporotic fragility fracture risk identified in 12 prospective population-based cohorts studies (n = 59,644) [<a class=\"bibliography-reference internal-reference\" href=\"/topics/osteoporosis-prevention-of-fragility-fractures/references/\">Kanis, 2008</a>].</li></ul><!-- end field f7537ccb-acf4-4bab-9c57-c67ca59793b4 --><!-- end item bf5d71f7-4832-40d7-b021-79086ca58f19 -->","subChapters":[]}]},{"id":"2a5fa14c-96c5-51a9-816e-e00b63898210","slug":"follow-up","fullItemName":"Follow up","depth":3,"htmlHeader":"<!-- begin field adbd08a0-fef0-41b5-b552-8fa41285b4b1 --><h3>How should I follow up a person at risk of fragility fracture?</h3><!-- end field adbd08a0-fef0-41b5-b552-8fa41285b4b1 -->","summary":null,"htmlStringContent":"<!-- begin item 0762462a-5ec9-4359-ae08-c2533b3e7b9e --><!-- begin field a3e9c3f7-3506-478b-8183-3ff96e53ef24 --><ul><li><strong>After starting bone-sparing treatment </strong>(see the section <a class=\"topic-reference internal-reference\" href=\"/topics/osteoporosis-prevention-of-fragility-fractures/management/management/#drug-treatment\">What drug treatments are recommended for people at high risk of osteoporotic fracture?</a>)<strong> and at routine medication review:</strong><ul><li><strong>Ask about adverse effects of bisphosphonate treatment, if appropriate, in particular</strong><strong>:</strong><ul><li><strong>Upper gastrointestinal adverse effects, </strong>such as dyspepsia or reflux. These are common in the first month of treatment and often improve with continuing use. They are less likely if the recommended method of taking bisphosphonates is followed. See the section on <a class=\"topic-reference internal-reference\" href=\"/topics/osteoporosis-prevention-of-fragility-fractures/prescribing-information/bisphosphonates/#advice\">What advice should I give someone taking bisphosphonates?</a></li><li><strong>Symptoms of atypical fracture, </strong>including new onset hip, groin, or thigh pain. If this occurs, stop treatment and arrange an X-ray of the femur.</li></ul></li><li><strong>Ask about adherence to treatment.</strong><ul><li>See the section on <a class=\"topic-reference internal-reference\" href=\"/topics/osteoporosis-prevention-of-fragility-fractures/management/management/#drug-treatment\">drug treatment</a> for recommended alternative treatments if adverse effects are unacceptable.</li><li>Consider prescribing a weekly dose of bisphosphonates for people who have difficulty adhering to daily treatment. For further information, see the section on <a class=\"topic-reference internal-reference\" href=\"/topics/osteoporosis-prevention-of-fragility-fractures/prescribing-information/\">Prescribing information</a>.</li></ul></li></ul></li><li><strong>For people taking oral corticosteroids:</strong><ul><li><strong>Continue treatment with bisphosphonates and/or calcium and vitamin D until treatment with oral corticosteroids has stopped</strong>, then reassess the osteoporotic fragility fracture risk to determine the need for continuing treatment with a bisphosphonate and calcium and vitamin D. See the section on <a class=\"topic-reference internal-reference\" href=\"/topics/osteoporosis-prevention-of-fragility-fractures/management/assessment/#how-to-assess\">How should I assess a person for fragility fracture risk?</a> for more information.</li></ul></li><li><strong>For all other people,</strong> review the need for continuing treatment with bisphosphonates after 3–5 years.<ul><li>For people who remain at high risk of an osteoporotic fragility fracture, continue treatment with alendronic acid for up to 10 years, and risedronate for up to 7 years. This includes people with any of the following risk factors:<ul><li>Age over 75 years.</li><li>A previous hip or vertebral fracture.</li></ul></li><li>In other people, arrange a dual-energy X-ray absorptiometry (DXA) scan and consider:<ul><li>Continuing treatment if the T-score is less than -2.5. Reassess their fracture risk and bone mineral density (BMD) every 3–5 years.</li><li>Stopping treatment if the BMD T-score is greater than -2.5. Reassess their fracture risk and re-measure BMD after 2 years.</li></ul></li></ul></li><li><strong>For people who sustain an osteoporotic fracture while on bone-sparing treatment, </strong>check adherence to treatment and exclude secondary causes for osteoporosis. If other underlying causes are excluded, consider referral to a specialist for advice on drug treatment. Drug treatment is recommended for at least 5 years to reduce the risk of further fractures. </li><li><strong>For people whose fracture risk was intermediate</strong> <strong>the last time they were assessed,</strong> reassess after a minimum of 2 years. See the section on <a class=\"topic-reference internal-reference\" href=\"/topics/osteoporosis-prevention-of-fragility-fractures/management/assessment/#how-to-assess\">How should I assess a person for fragility fracture risk?</a> for more information.</li></ul><!-- end field a3e9c3f7-3506-478b-8183-3ff96e53ef24 --><!-- end item 0762462a-5ec9-4359-ae08-c2533b3e7b9e -->","subChapters":[{"id":"9d35d3d1-a267-5813-8430-67a488a7cd18","slug":"basis-for-recommendation-b9f","fullItemName":"Basis for recommendation","depth":4,"htmlHeader":"<!-- begin field 33db7bd6-7ab9-4e11-ba10-39059a86b8b6 --><h4>Basis for recommendation</h4><!-- end field 33db7bd6-7ab9-4e11-ba10-39059a86b8b6 -->","summary":null,"htmlStringContent":"<!-- begin item b9f92ad6-e579-48ee-9abb-c7ca0519634a --><!-- begin field 492f8e52-bab6-41ea-b203-bb49fb135236 --><p>These recommendations are based on the National Institute for Health and Care Excellence (NICE) guideline <em>Osteoporosis: assessing the risk of fragility fracture</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/osteoporosis-prevention-of-fragility-fractures/references/\">NICE, 2012b</a>], the Scottish Intercollegiate Guidelines Network (SIGN) guideline <em>Management of osteoporosis and the prevention of fragility fractures</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/osteoporosis-prevention-of-fragility-fractures/references/\">SIGN, 2015</a>], the National Osteoporosis Guideline Group (NOGG) guideline <em>Osteoporosis: clinical guideline for prevention and treatment</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/osteoporosis-prevention-of-fragility-fractures/references/\">NOGG, 2016</a>], and a randomized double-blind placebo controlled trial [<a class=\"bibliography-reference internal-reference\" href=\"/topics/osteoporosis-prevention-of-fragility-fractures/references/\">Black, 2006</a>].</p><h5>Duration of bone-sparing treatment</h5><ul><li>For people taking oral corticosteroids, the recommendation to continue treatment with a bisphosphonate at least until oral corticosteroids are stopped is based on expert opinion in the NOGG guideline [<a class=\"bibliography-reference internal-reference\" href=\"/topics/osteoporosis-prevention-of-fragility-fractures/references/\">NOGG, 2016</a>].</li><li>The recommendation to continue treatment with a bisphosphonate after 5 years for people at continued high risk of a fragility fracture is based on expert opinion in the NOGG guideline [<a class=\"bibliography-reference internal-reference\" href=\"/topics/osteoporosis-prevention-of-fragility-fractures/references/\">NOGG, 2016</a>].</li><li>The recommendation to stop bisphosphonate treatment after 3–5 years (depending on the bone mineral density) is aimed at reducing the possibility of long-term skeletal adverse effects of bisphosphonates (such as atypical subtrochanteric fractures) [<a class=\"bibliography-reference internal-reference\" href=\"/topics/osteoporosis-prevention-of-fragility-fractures/references/\">NOGG, 2016</a>]. However, be aware that:<ul><li>There is a lack of evidence that 'drug holidays' reduce the incidence of skeletal adverse effects of bisphosphonates [<a class=\"bibliography-reference internal-reference\" href=\"/topics/osteoporosis-prevention-of-fragility-fractures/references/\">SIGN, 2015</a>].</li><li>A 'drug holiday' after 3–5 years of treatment with alendronate is associated with only a small increase in clinically apparent vertebral fractures with no increase in other types of osteoporotic fractures [<a class=\"bibliography-reference internal-reference\" href=\"/topics/osteoporosis-prevention-of-fragility-fractures/references/\">Black, 2006</a>].</li></ul></li></ul><h5>Management of people who sustain a fracture while on bone-sparing treatment</h5><ul><li>These recommendations are based on expert opinion in the NOGG guideline [<a class=\"bibliography-reference internal-reference\" href=\"/topics/osteoporosis-prevention-of-fragility-fractures/references/\">NOGG, 2016</a>].</li></ul><!-- end field 492f8e52-bab6-41ea-b203-bb49fb135236 --><!-- end item b9f92ad6-e579-48ee-9abb-c7ca0519634a -->","subChapters":[]}]}]}}},"staticQueryHashes":["3666801979"]}